Digital PCR Market to Record a 22.2% CAGR from 2023 to 2030; Prevalence of Diseases, Product Innovations, Acquisitions, and Adoption of dPCR in Laboratories to Foster Market Growth

The global digital PCR market size was valued at USD 485.1 million in 2022. The market is projected to grow from USD 584.5 million in 2023 to USD 2,379.9 million by 2030, exhibiting a CAGR of 22.2% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Digital PCR Market Size, Share & COVID-19 Impact Analysis, By Type (Droplet Digital PCR, Chip-based Digital PCR, and Others), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End-user (Hospital & Clinics, Pharmaceutical & Biotechnology Industries, Clinical Laboratories, and Academic & Research Organizations), and Regional Forecast, 2023-2030”.

The market is expected to witness growth due to various factors, including the increasing prevalence of infectious diseases, cancer, and genetic disorders. Additionally, the introduction of new products, rise in acquisitions, growing adoption of digital polymerase chain reaction (PCR) by laboratories, and advancements in digital devices technology are projected to play a significant role in fostering market growth throughout the forecast period.

Rise in COVID-19 Testing and Reallocation of Healthcare Resources Generated Revenue for Companies

The redirection of healthcare resources toward COVID-19 treatment led to a rise in the number of individuals seeking COVID-19 diagnosis. This, in turn, increased the adoption of dPCR devices in diagnostic centers and research institutes, resulting in a surge in demand for these devices. Furthermore, the global increase in COVID-19 testing, particularly in high-burden countries, had a positive impact on the market. In the early stages of the pandemic, resources were primarily allocated to combat the highly infectious nature of the disease. As a result, market players experienced significant revenue growth in 2020.

Stilla and Promega Corporation Strengthened PCR Workflow Solutions through Co-Marketing Agreement

Stilla and Promega Corporation entered into a co-marketing agreement aimed at enhancing their digital Polymerase Chain Reaction (PCR) workflow solutions in April 2022. The collaboration focused on combining sample preparation using the latest Maxwell systems with the six-color Naica system for dPCR. This strategic partnership between the two companies aimed to strengthen their offerings in the market and provide more comprehensive workflow solutions for customers.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/digital-pcr-market-102014

Advantages of Digital Polymerase Chain Reaction (dPCR) Drive Adoption over Real-Time Devices
Digital Polymerase Chain Reaction (dPCR) offers several advantages over real-time devices, particularly in terms of delivering a complete measure of target nucleic acid molecules. Unlike relative measures obtained from real-time devices, dPCR enables absolute DNA quantification, ensuring enhanced reproducibility, sensitivity, and precision. This capability allows researchers to quantify smaller differences and precisely measure minor variants in nucleic acid samples. As a result, these distinct advantages associated with digital devices are expected to drive the adoption of dPCR technology during the forecast period.

However, the relatively higher price of digital devices compared to alternative options has the potential to impede the digital PCR market growth.

Consolidation and Strategic Initiatives Drive Market Growth for Key Companies

The market is consolidated, with key companies holding significant market shares. Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and Qiagen are prominent players operating in the market. Qiagen N.V. is currently emphasizing inorganic strategies, such as collaborations with new manufacturers of dPCR devices, to expand its product portfolio globally. These initiatives are contributing to the growth of the company in the market.

Key Industry Development

• May 2020- Bio-Rad Laboratories, Inc. received approval from the U.S. Food and Drug Administration (FDA) for SARS CoV-2 Droplet dPCR test kit.

List of Companies Profiled in the Report

• QIAGEN (Germany)


• Thermo Fisher Scientific Inc. (U.S.)


• Bio-Rad Laboratories, Inc. (U.S.)


• JN Medsys (Singapore)


• Stilla (France)


• Sysmex Corporation (Japan)


• Standard BioTools Inc. (U.S.)


• Precigenome LLC. (U.S.)

Further Report Findings:

• North America dominated the digital PCR market share in 2022 with a valuation of USD 213.4 million. This can be attributed to factors such as a highly vigilant and economically stable population along with an increasing adoption of advanced and high-cost diagnostic solutions in the region.


• Asia Pacific is expected to experience growth due to improvements in healthcare infrastructure. Additionally, the region faces a high burden of both chronic and infectious diseases, necessitating the use of efficient diagnostic tools.

Table of Segmentation